Holen Sie sich die Stockscreener-App
1.17
8.33%
0.09
Handel nachbörslich:
1.18
0.01
+0.85%
Schlusskurs vom Vortag:
$1.08
Offen:
$1.07
24-Stunden-Volumen:
72,582
Relative Volume:
0.31
Marktkapitalisierung:
$2.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.64M
KGV:
-0.0647
EPS:
-18.0702
Netto-Cashflow:
$-5.60M
1W Leistung:
+17.19%
1M Leistung:
+2.63%
6M Leistung:
-97.10%
1J Leistung:
-97.16%
1-Tages-Spanne:
$1.07
$1.18
1-Wochen-Bereich:
$0.89
$1.18
52-Wochen-Spanne:
$0.5949
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare CMND vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.17 | 2.59M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
CMND PE Ratio & Valuation, Is CMND Overvalued - Intellectia AI
Clearmind gets safety board approval to continue AUD trial - Investing.com
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial - TipRanks
Bull Bear: What analysts say about Clearmind Medicine Inc stockWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Clearmind completes treatment for 18 participants in AUD trial By Investing.com - Investing.com Australia
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
[EFFECT] Clearmind Medicine Inc. SEC Filing - Stock Titan
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - MarketScreener
Clearmind completes treatment for 18 participants in AUD trial - Investing.com
Clearmind Medicine Announces Successful Completion Of Treatment Of Cmnd-100 For Alcohol Use Disorder - TradingView
Clearmind Medicine (Nasdaq: CMND) completes treatment for 18 CMND-100 patients - Stock Titan
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - bitget.com
Clearmind says its alcohol disorder drug trial cleared 18 patients - Stock Titan
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Clearmind files patent application in India for psychedelic compounds By Investing.com - Investing.com South Africa
Clearmind files patent application in India for psychedelic compounds - in.investing.com
Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders - TradingView
Clearmind Medicine Inc. Files Patent Application in India for Next-Generation Psychedelic Compounds Targeting Mental Health and Addiction - Quiver Quantitative
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to ... - Caledonian Record
Market Overview: Is Clearmind Medicine Inc in a bullish channel2026 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
[POS AM] Clearmind Medicine Inc. SEC Filing - Stock Titan
CMND SEC FilingsClearmind Medici 10-K, 10-Q, 8-K Forms - Stock Titan
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Analyst Upgrade: Is Clearmind Medicine Inc a turnaround story2026 Catalysts & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Form 6K Clearmind Medicine Inc For: 19 March - Investing.com
[6-K] Clearmind Medicine Inc. Cur... | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - manilatimes.net
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Aug Patterns: How do insiders feel about Clearmind Medicine Inc - baoquankhu1.vn
Clearmind Medicine secures six patents in Hong Kong - Investing.com
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies - The Manila Times
Clearmind Medicine Inc. Announces Publication of Six Patents in Hong Kong for Novel Psychedelic Combination Therapies - Quiver Quantitative
Six new Hong Kong combo patents for Clearmind (Nasdaq: CMND) - Stock Titan
Six Clearmind psychedelic drug combos published as Hong Kong patents - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc discloses patent application for depression yherapy - TipRanks
NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing - TipRanks
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - TheNewswire
NeuroThera LabsClearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Yahoo Finance
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):